UTHR

NASDAQ Healthcare

United Therapeutics Corporation - Common Stock

Drug Manufacturers - Specialty & Generic

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

๐Ÿ“Š Market Data
Price$570.40
Volume172,207
Market Cap24.21B
Beta0.750
RSI (14-Day)41.2
200-Day MA$455.29
50-Day MA$543.94
52-Week High$607.89
52-Week Low$272.12
P/E Ratio20.46
Forward P/E16.75
Price / Book3.51
๐ŸŽฏ Investment Strategy Scores

UTHR scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 41/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 58/100โ–ฒ +10
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 46/100โ–ฒ +10
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 18/100โ–ผ -10
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ‹ Institutional Whale (84/100) โ€” this strategy Large-cap, institutional-quality stocks.

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (18/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find UTHR in your text

Paste any article, transcript, or post โ€” the tool will extract UTHR and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.